Skip to main content
Quest Diagnostics

Evaluation of Automated Platforms for HSV-1 and HSV-2 IgG Serologic Testing

STI Prevention 2026

Atlanta, GA, Aug 31-Sep 2, 2026

Poster presentation: Evaluation of Automated Platforms for HSV-1 and HSV-2 IgG Serologic Testing

Authors: Shates T, Realegeno S, Marlowe EM

Medical Specialty: Infectious disease

Related content

On-Demand Webinar
Herpes simplex virus (HSV) diagnostics 2025: An overview
Test FAQ
Herpes Simplex Virus (HSV) Type-Specific IgG Antibodies, with Reflex to HSV-2 Inhibition
Publication
Validation of the Clinical Performance and Reproducibility of the Savanna HSV 1+2/VZV Assay
Publication
Chlamydia and Gonorrhea Testing in Pregnancy: Time to Improve Adherence and Update Recommendations
Publication
Review of the Performance of Laboratory-Based Molecular Diagnostics for Chlamydia trachomatis and Neisseria gonorrhoeae
Test FAQ
Chlamydia trachomatis Neisseria gonorrhoeae RNA TMA

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only. May include AI-generated and/or AI-modified imagery.